TY  - JOUR
A1  - Medler, Juliane
A1  - Kucka, Kirstin
A1  - Wajant, Harald
T1  - Tumor necrosis factor receptor 2 (TNFR2): an emerging target in cancer therapy
JF  - Cancers
N2  - Despite the great success of TNF blockers in the treatment of autoimmune diseases and the identification of TNF as a factor that influences the development of tumors in many ways, the role of TNFR2 in tumor biology and its potential suitability as a therapeutic target in cancer therapy have long been underestimated. This has been fundamentally changed with the identification of TNFR2 as a regulatory T-cell (Treg)-stimulating factor and the general clinical breakthrough of immunotherapeutic approaches. However, considering TNFR2 as a sole immunosuppressive factor in the tumor microenvironment does not go far enough. TNFR2 can also co-stimulate CD8\(^+\) T-cells, sensitize some immune and tumor cells to the cytotoxic effects of TNFR1 and/or acts as an oncogene. In view of the wide range of cancer-associated TNFR2 activities, it is not surprising that both antagonists and agonists of TNFR2 are considered for tumor therapy and have indeed shown overwhelming anti-tumor activity in preclinical studies. Based on a brief summary of TNFR2 signaling and the immunoregulatory functions of TNFR2, we discuss here the main preclinical findings and insights gained with TNFR2 agonists and antagonists. In particular, we address the question of which TNFR2-associated molecular and cellular mechanisms underlie the observed anti-tumoral activities of TNFR2 agonists and antagonists.
KW  - NFkappaB
KW  - regulatory T-cell (Treg)
KW  - tumor necrosis factor (TNF)
KW  - TNF receptor 2 (TNFR2)
KW  - TNF receptor associated factor 1 and 2 (TRAF1, TRAF2)
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-275143
SN  - 2072-6694
VL  - 14
IS  - 11
ER  -